Liraglutide (Victoza / Saxenda): An Evidence Review

Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it’s the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got the real drug) that measured real-world outcomes. So the honest job here is to separate what the evidence firmly backs up from the experimental and gray-market claims that tag along with it.

What it is

Liraglutide is a GLP-1 receptor agonist. In plain terms, it’s a slightly tweaked copy of GLP-1, a hormone your gut releases after you eat. It shares about 97% of its makeup with the natural hormone. Two small structural changes set it apart: one building block is swapped at position 34, and a fatty-acid (fat-like) chain is attached at another spot. That fatty tail makes the molecule grip tightly onto albumin, a protein in your blood (more than 98% of it stays bound to protein), and bunch together with copies of itself. Both tricks hide it from the enzyme that would normally chew up natural GLP-1 within minutes. The payoff is a half-life (the time it takes for half a dose to clear your body) of roughly 13 hours, which is long enough for a single daily injection.

When it switches on GLP-1 receptors in the pancreas, gut, and brain, it tells the body to release insulin when blood sugar is high, dials down glucagon (a hormone that raises blood sugar), slows how fast the stomach empties, and curbs appetite. Because it only nudges insulin up when blood sugar is already high, liraglutide on its own rarely causes dangerously low blood sugar. It’s sold as Victoza (for type 2 diabetes), Saxenda (a higher-dose version for long-term weight management), and as part of a fixed combination called Xultophy, which pairs it with insulin degludec.

The claims

The mainstream, label-backed claims are simple: better blood-sugar control in type 2 diabetes, real weight loss, and a lower risk of heart attack and stroke in diabetic patients who are already at high risk. In research settings, liraglutide has also been tested for fatty liver disease (NASH/MASH, a buildup of fat and inflammation in the liver), Alzheimer’s disease, and PCOS (polycystic ovary syndrome). Online and gray-market sellers pitch it more loosely for cosmetic weight loss and “metabolic optimization,” without the prescription, screening, and monitoring that come with the approved product.

The evidence

The approved uses are backed by large randomized controlled trials, not just personal stories.

• Blood sugar (LEAD program): Six randomized, double-blind phase-3 trials enrolled over 4,000 adults with type 2 diabetes across 40 countries. Liraglutide lowered HbA1c (a three-month average of blood sugar) by up to about 1.5%, generally beating comparison drugs such as sitagliptin, glimepiride, and insulin glargine, with modest weight loss and nausea as the main side effect.
• Heart outcomes (LEADER): This is the strongest evidence. In a randomized, double-blind, placebo-controlled trial of 9,340 adults with type 2 diabetes at high heart risk, followed for a median of 3.8 years, liraglutide cut the main combined measure of heart-related death, nonfatal heart attack, and nonfatal stroke (HR 0.87, meaning roughly a 13% lower risk), reduced heart-related death (HR 0.78), and reduced death from any cause (HR 0.85). Notably, this trial was co-funded by the NIH (the US National Institutes of Health) alongside Novo Nordisk.
• Weight (SCALE): In a 56-week, double-blind pivotal trial of 3,731 adults without diabetes, the 3.0 mg dose plus lifestyle counseling produced average weight loss of about 8.4 kg versus 2.8 kg on placebo.
• Pediatric diabetes (Ellipse): In a placebo-controlled trial in children aged 10 to under 17, liraglutide added to metformin improved HbA1c over 52 weeks, with more stomach and gut side effects and — notably — no extra weight loss.

The experimental uses are far weaker. The LEAN trial in fatty liver disease was a single small phase-2 study of just 52 patients; it showed promising improvement in liver tissue (NASH resolution in 39% versus 9% on placebo) but is only a starting point for further research, not proof. In Alzheimer’s disease, the ELAD phase-2b trial (204 participants, published 2025) failed its main goal — there was no meaningful effect on how the brain uses glucose (p=0.14, meaning the result could easily be chance). A few secondary cognitive measures hinted at slower decline, but those aren’t confirmation.

Two honest caveats apply to the whole picture. First, almost all of the pivotal trials were funded by the maker, Novo Nordisk; LEADER’s independent NIH co-funding is the main exception. Second, there’s no long-term trial measuring real outcomes for the 3.0 mg obesity dose in people without diabetes, and liraglutide is now seen as weaker for weight loss than newer drugs like semaglutide and tirzepatide. The animal data often quoted for benefits to beta cells (the cells that make insulin) are also shakier than the headlines suggest — one well-known mouse study, titled as if it showed more beta-cell mass, actually reported only a “strong tendency,” not a statistically meaningful increase. It’s the human trials, not the animal work, that earn the grade.

Safety and side effects

The most common effects involve the stomach and gut, depend on the dose, and usually ease over time: nausea (around 20%), diarrhea, headache, vomiting, reduced appetite, indigestion, and constipation.

Liraglutide carries a boxed warning (the FDA’s most serious warning) for thyroid C-cell tumors, based on findings in rats and mice; whether this carries over to humans is still unknown. It should not be used by people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2 syndrome (an inherited condition that raises the risk of certain tumors).

Pancreatitis (inflammation of the pancreas) has been a recurring concern. Acute pancreatitis, including severe cases, has been reported after the drug went on sale, and it should be stopped if pancreatitis is suspected. But the early worry about a cause-and-effect link wasn’t borne out by regulators: a 2014 joint FDA–EMA review concluded the data didn’t support liraglutide causing pancreatitis or pancreatic cancer. A pooled analysis of liraglutide trials reached the same overall conclusion, though to be candid, it did find a small numerical gap — 1.6 versus 0.7 acute pancreatitis cases per 1,000 patient-years — which the authors judged too small to prove cause and effect. A separate study based on insurance claims data also found no clear rise in risk.

Other documented label items include gallbladder disease (gallstones and gallbladder inflammation, partly tied to weight loss), low blood sugar when combined with insulin or sulfonylureas (another class of diabetes drug), kidney injury (often alongside dehydration from vomiting or diarrhea), faster heart rate, allergic reactions, and — for Saxenda — watching for suicidal thoughts. This is not medical advice; the approved product requires a prescription and clinical monitoring.

Legal and regulatory status

Liraglutide is an approved prescription drug, not a supplement or research chemical. The FDA approved Victoza for type 2 diabetes on January 25, 2010, and Saxenda for long-term weight management on December 23, 2014 — the first GLP-1 analogue approved for obesity, later expanded to teenagers. The EMA (the European Medicines Agency) authorized Victoza in 2009 and Saxenda in March 2015.

For athletes: as of the 2026 WADA Prohibited List (the World Anti-Doping Agency’s official banned-substance list), GLP-1 receptor agonists are not prohibited. The related drugs semaglutide and tirzepatide sit on WADA’s Monitoring Program, which simply tracks their use without any penalty; liraglutide isn’t individually named as banned. Claims floating around on some supplement-vendor pages that GLP-1 drugs were fully banned in January 2026 are contradicted by trustworthy sources and shouldn’t be believed — always check the official WADA list.

Branded liraglutide is prescription-only in the US and EU. Anything sold online as a “research peptide” comes with no guarantee that it’s the right substance, pure, sterile, or accurately dosed, and it skips the boxed warning, the screening for who shouldn’t take it, and the safety monitoring that govern the approved product.

Bottom line

For its two approved uses — controlling blood sugar in type 2 diabetes and managing weight long-term — liraglutide is a genuinely effective drug backed by large, repeated trials, with risks that are real but generally manageable under medical supervision. Its heart benefit in high-risk diabetic patients is among the best-documented findings in its class. The honest qualifications are that most trials were funded by the maker, the experimental uses (fatty liver, Alzheimer’s) are preliminary or flat-out negative, and newer GLP-1 drugs now deliver more weight loss. The grade applies to the approved uses, not the gray-market promises.

Evidence grade: 10/10 · Established.

Sources

• Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine, 2016
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). New England Journal of Medicine, 2015
• Tamborlane WV et al. Liraglutide in Children and Adolescents with Type 2 Diabetes (Ellipse). New England Journal of Medicine, 2019
• Liraglutide phase 3 (LEAD) programme overview. PubMed
• LEAD 1–5 overview. PubMed
• Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN). The Lancet, 2016
• Femminella GD et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial (ELAD). Nature Medicine, 2025 (PMC)
• Egan AG et al. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. New England Journal of Medicine, 2014
• Jensen TM et al. Is There a Link Between Liraglutide and Pancreatitis? Diabetes Care, 2015
• Funch D et al. Claims-based assessment of pancreatitis and pancreatic cancer risk with liraglutide. PubMed, 2014
• Victoza label and boxed warning. DailyMed
• Novo Nordisk receives FDA approval for Saxenda (December 23, 2014). GlobeNewswire
• Victoza approval history. Drugs.com
• Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. ACS Pharmacology & Translational Science, 2019
• GLP-1 receptor agonists monitored at the 2026 Winter Olympics. EMJ Reviews
• WADA Prohibited List